David Lebwohl

David’s career spans three decades in the biopharmaceutical industry, successfully bringing novel medicines through all phases of clinical trials and global regulatory approvals. He has overseen multiple full-scale development programs with more than 200 clinical studies across myriad indications. Currently, David is chief medical officer at Intellia Therapeutics. Before Intellia, David was chief medical officer at Semma Therapeutics Inc., a subsidiary of Vertex Pharmaceuticals Inc., where he was leading the company’s regenerative medicine efforts using stem-cell-derived pancreatic islets to cure type I diabetes. Prior to his role at Semma Therapeutics, David held numerous senior-level positions leading drug development at the global healthcare company Novartis Pharmaceuticals, Inc. There, he was most recently Senior Vice President and franchise global program head, CAR-T, Promacta and SEG101 Global Program Teams, responsible for the development of the breakthrough therapy Kymriah® (tisagenlecleucel), approved for the treatment of B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. During his time at Novartis, David was responsible for numerous oncology drug development programs. Under his leadership, the blockbuster drug Afinitor® (everolimus) was approved for five indications including metastatic breast, neuroendocrine, and kidney cancer as well as the rare genetic disease tuberous sclerosis. Prior to working at Novartis, David led oncology development teams at the Bristol Myers Squibb Inc. Pharmaceutical Research Institute for five years. He is a well-recognized medical oncologist, with certifications in hematology and internal medicine. David received an undergraduate degree in Biochemical Sciences from Harvard College and an MD from the Yale University School of Medicine. He completed his fellowship training at Memorial Sloan Kettering Cancer Center and his residency in Internal Medicine at Brigham and Women’s Hospital in Boston. David has authored more than 50 peer-reviewed publications and is a member of the American Society of Clinical Oncology.